EVERSANA, a global provider of commercial services to the life sciences industry, has announced the opening of a new office in Berlin, Germany, further expanding its European presence. This development comes as part of the company’s ongoing commitment to investing in infrastructure to support pharmaceutical clients in one of the world’s largest markets.
Germany, the largest pharmaceutical market in Europe and the fourth-largest globally, is a critical hub for drug development and commercialisation. The new office, situated in the Carre am Schnikelplatz building in central Berlin, marks EVERSANA’s latest effort to enhance its global footprint. The Berlin office is intended to serve both employees and clients, offering a dedicated space for meetings and strategic operations across the region.
Supporting life sciences growth
Jim Lang, Chief Executive Officer of EVERSANA, explained the significance of the move: “Over the years we have made smart, strategic investments in the services, talent, and locations needed to transform the global commercialisation of life-changing therapies. Germany represents the fourth-largest pharmaceutical market in the world and is often the first country in which our clients strategically launch new therapies in Europe. We have the local expertise and operations in Germany to help our clients and their products thrive.”
The opening of this office follows a broader trend within EVERSANA’s global strategy to bolster commercialisation support for life sciences companies worldwide. The company, which provides a wide range of services from pricing and market access to medical communications and patient support, operates in more than 15 countries globally, with this new Berlin location enhancing their European offering.
Berlin office opens ahead of key healthcare conference
The new facility opens in time for the annual Frontiers Health Conference, which will take place in Berlin this October. This prestigious event brings together healthcare professionals, innovators, and executives from across the globe to discuss the latest advancements in health technology and life sciences. EVERSANA will play a prominent role at the conference, with several key executives, including Jim Lang, Roberto Ascione (President, Health Innovation), and Mike Ryan (General Manager, Europe), scheduled to speak at the event.
Jim Lang emphasised the importance of the conference: “The Frontiers Health Conference is a key event in the healthcare calendar, offering a platform for leaders in the sector to share insights, connect with innovators, and discuss the future of health technology. We are excited to welcome clients and colleagues from around the world to Berlin.”
EVERSANA has been instrumental in driving innovation in the life sciences industry by offering comprehensive solutions that cover the entire commercialisation lifecycle, from pre-launch strategy to post-market support. The company’s decision to expand its operations in Europe reflects its ongoing commitment to improving access to life-changing therapies through enhanced commercial services.
The Berlin office is expected to play a key role in supporting EVERSANA’s efforts to help pharmaceutical companies bring new treatments to market quickly and efficiently. This latest expansion highlights Germany’s pivotal role in the life sciences sector, particularly as a launching point for innovative therapies in Europe.
For more information about the Frontiers Health Conference, interested parties can visit the event’s website and use the promotional code FHEVS20 to receive a 20% discount on registration.
